| Convalescent Plasma (factors from those who have survived Ebola infection) shows promise as a treatment for the disease. [[Ribavirin]] is ineffective. [[Interferon]] is also thought to be ineffective. In monkeys, administration of an inhibitor of coagulation (rNAPc2) has shown some benefit, protecting 33% of infected animals from a usually 100% (for monkeys) lethal infection<ref name="pmid14683653">{{cite journal| author=Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J et al.| title=Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. | journal=Lancet | year= 2003 | volume= 362 | issue= 9400 | pages= 1953-8 | pmid=14683653 | doi=10.1016/S0140-6736(03)15012-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14683653 }} </ref> (unfortunately this inoculation does not work on humans). In early 2006, scientists at [[USAMRIID]] announced a 75% recovery rate after infecting four [[rhesus monkey]]s with Ebola virus and administering [[Antisense therapy|antisense drugs]]<ref name="pmid16703508">{{cite journal| author=Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K et al.| title=Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. | journal=J Infect Dis | year= 2006 | volume= 193 | issue= 12 | pages= 1650-7 | pmid=16703508 | doi=10.1086/504267 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16703508 }} </ref>. Postexposure [[vaccination]] with different viruses ([[vesicular stomatitis virus]])<ref name="pmid15113924">{{cite journal| author=Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Möller P, Wagner R et al.| title=Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. | journal=J Virol | year= 2004 | volume= 78 | issue= 10 | pages= 5458-65 | pmid=15113924 | doi= | pmc=PMC400370 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15113924 }} </ref><ref name="pmid17238284">{{cite journal| author=Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A et al.| title=Effective post-exposure treatment of Ebola infection. | journal=PLoS Pathog | year= 2007 | volume= 3 | issue= 1 | pages= e2 | pmid=17238284 | doi=10.1371/journal.ppat.0030002 | pmc=PMC1779298 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17238284 }} </ref> and [[passive immunization]] with [[blood]] or [[serum]]<ref name="pmid9988160">{{cite journal| author=Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M et al.| title=Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. | journal=J Infect Dis | year= 1999 | volume= 179 Suppl 1 | issue= | pages= S18-23 | pmid=9988160 | doi=10.1086/514298 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9988160 }} </ref>, or recombinant human [[monoclonal antibodies]]<ref name="pmid10364354">{{cite journal| author=Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST et al.| title=Ebola virus can be effectively neutralized by antibody produced in natural human infection. | journal=J Virol | year= 1999 | volume= 73 | issue= 7 | pages= 6024-30 | pmid=10364354 | doi= | pmc=PMC112663 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10364354 }} </ref> from human survivors have been tested with non-conclusive results.
| |